Autopsy report · NCT02949843

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

“Slow accrual, closed by IRB”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 3 years 10 months before it stopped.
• 19 participants enrolled.
• Results were posted on the registry 3 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Wake Forest University Health Sciences

Sponsor type

University, hospital or other

Conditions

EGFR Activating Mutation; Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer

Interventions

Chemotherapy; Immunotherapy; Laboratory Biomarker Analysis; Nivolumab; Pembrolizumab; Targeted Molecular Therapy

Participants

19

Sites

1

Countries

United States

Trials that died the same way

• Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
  “Closed due to very slow accrual” (70% match in meaning)
• Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
  “Slow accrual; closed by funder” (70% match in meaning)
• Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
  “slow accrual” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.